1. Home
  2. TYRA vs TROX Comparison

TYRA vs TROX Comparison

Compare TYRA & TROX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tyra Biosciences Inc.

TYRA

Tyra Biosciences Inc.

N/A

Current Price

$20.07

Market Cap

1.3B

Sector

Health Care

ML Signal

N/A

Logo Tronox Holdings plc (UK)

TROX

Tronox Holdings plc (UK)

N/A

Current Price

$3.67

Market Cap

1.3B

Sector

Industrials

ML Signal

N/A

Company Overview

Basic Information
Metric
TYRA
TROX
Founded
2018
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Major Chemicals
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.3B
IPO Year
2021
2012

Fundamental Metrics

Financial Performance
Metric
TYRA
TROX
Price
$20.07
$3.67
Analyst Decision
Strong Buy
Hold
Analyst Count
15
8
Target Price
★ $47.45
$5.81
AVG Volume (30 Days)
957.1K
★ 2.0M
Earning Date
11-04-2026
11-04-2026
Dividend Yield
N/A
★ 5.29%
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $2,898,000,000.00
Revenue This Year
N/A
$13.36
Revenue Next Year
N/A
$4.18
P/E Ratio
★ N/A
N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$13.35
$2.86
52 Week High
$40.65
$10.59

Technical Indicators

Market Signals
Indicator
TYRA
TROX
Relative Strength Index (RSI) 35.51 26.04
Support Level $18.66 N/A
Resistance Level $27.00 $4.53
Average True Range (ATR) 1.12 0.18
MACD -0.14 0.02
Stochastic Oscillator 7.94 3.41

Price Performance

Historical Comparison
TYRA
TROX

About TYRA Tyra Biosciences Inc.

Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are FGFR3, FGFR4/3, and FGFR1/2/3: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.

About TROX Tronox Holdings plc (UK)

Tronox Holdings PLC is a vertically integrated manufacturer of TiO2 pigment. It operates titanium-bearing mineral sand mines and beneficiation and smelting operations in Australia & South Africa to produce feedstock materials that can be processed into TiO2 for pigment, high-purity titanium chemicals, including titanium tetrachloride, and ultrafine TiO2 used in certain specialty applications. TiO2 and titanium feedstock, are used to produce paints and coatings, as well as plastics, paper, and printing ink. It has three pigment production facilities in the United States, the Netherlands, and Western Australia and three mining operations in Western Australia and South Africa. Europe, the Middle East, and Africa regions contribute the majority of revenue.

Share on Social Networks: